** Shares of Avadel Pharmaceuticals AVDL.O fall ~25% to $8.01 premarket

** Late on Wednesday AVDL forecast 2025 rev in the range of $240 mln to $260 mln

** Analysts on average estimate total revenue of about $267.6 mln -LSEG data

** At least two brokerages cut PT on AVDL following the disappointing 2025 outlook

** H.C.Wainwright analysts expect a slower revenue ramp up for its sleep disorder drug Lumryz

** Up to last close, stock down ~32% over the past 12 months

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))